Anti-PD-1 Antibody CDR Composition for Specific PD-1 Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immune therapies targeting PD-1 for treating cancers and immune disorders are limited in efficacy and specificity, necessitating the development of new and improved antibodies that can enhance immune responses and inhibit the interaction between PD-1 and its ligands.
Innovation Solution
Development of novel recombinant anti-PD-1 antibodies with specific H-CDR1-3 and L-CDR1-3 amino acid sequences, which exhibit high affinity and specificity for human PD-1, inhibiting the PD-1/PD-L1 interaction, and enhancing immune responses through increased cytokine secretion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If currently available anti-PD-1 antibody treatments are used, then immune response is enhanced, but efficacy and specificity are limited
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequences of the antibody's complementarity-determining regions (CDRs), specifically H-CDR1-3 and L-CDR1-3, to optimize binding affinity and specificity. This involves changing the molecular parameters of the antibody structure to achieve superior clinical response while maintaining immune enhancement capabilities.
2Adaptability or versatility
If currently available anti-PD-1 antibody treatments are used, then immune response is enhanced, but specificity is limited
Solution Approach 1:
The patent modifies specific amino acid parameters in the CDR regions to enhance binding specificity for human PD-1. By changing the molecular composition and structure of the antibody's antigen-binding sites, the invention achieves both improved specificity and maintained or enhanced efficacy in treating cancers.
3Reliability
If novel recombinant antibodies with specific amino acid sequences are developed, then binding affinity and immune activation are enhanced, but development complexity increases
Solution Approach 1:
The patent applies segmentation by focusing development efforts on specific functional segments of the antibody molecule, namely the six CDR sequences (H-CDR1-3 and L-CDR1-3). By identifying and optimizing these critical segments independently, the complex development process is broken down into manageable parts, reducing overall development complexity while achieving enhanced binding affinity.
Solution Approach 2:
The invention changes specific amino acid parameters in the CDR regions to optimize binding affinity. By systematically modifying and selecting sequences based on their binding properties, the patent reduces the complexity of developing high-affinity antibodies through a more directed and parameter-focused approach.
Data Source
Figure 1~2
Figure 3A~3B
Figure 3C
AI summary
This invention relates to anti-PD-1 antibodies and methods of using them in treating diseases and conditions related to PD-1activity, e.g., cancer.